{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 38,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a pyramid diagram to represent the evolution of oncolytic virus technology, with Genelux's platform at the top.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/10",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.45,
        "x": 0.22,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Pyramid showing 7 completed clinical trials, ~150 patients, and key technical advantages like Systemic Dosing and Robust Immune Activation.",
      "attrs": null,
      "subkind": "pyramid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d53d6705-30d4-47b9-a5ee-b288900a52ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "image",
      "text": "Genelux logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7838e10-afee-45c9-9a0e-71bce2cd1b0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.68,
        "y": 0.75
      },
      "kind": "subtitle",
      "text": "Commercial/Late-stage 1st Generation viruses confirm modality's potential, but all are limited to local delivery and scope of addressable cancers",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52ed6901-c443-45b3-b8bc-127a41edc8b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "subtitle",
      "text": "Olvi-Vec has the potential to redefine the oncolytic virus space and provide utility across multiple tumor types by enabling physician-preferred administration techniques and setting new benchmarks in efficacy and safety.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55d86b7d-ec2e-479f-8ab5-2bd18840a38f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Creating a New Paradigm Of Oncolytic Virus Drug Development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1216693-1a02-45b1-84dc-d86ba5833ed5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "pyramid",
      "slug": null,
      "matchId": "370325ca-b221-40af-9d02-38b864c59700",
      "evidence": "Visual hierarchy of technology evolution",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}